{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T05:45:16Z","timestamp":1771998316867,"version":"3.50.1"},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,1]]},"DOI":"10.1093\/ageing\/afx103","type":"journal-article","created":{"date-parts":[[2017,6,12]],"date-time":"2017-06-12T15:11:04Z","timestamp":1497280264000},"page":"9-17","source":"Crossref","is-referenced-by-count":64,"title":["Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-regression analysis"],"prefix":"10.1093","volume":"47","author":[{"given":"Ying","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Dong","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hai","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0594-8576","authenticated-orcid":false,"given":"Alena","family":"Shantsila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Fauchier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Sheng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,9,8]]},"reference":[{"key":"key\n\t\t\t\t20180103092541_afx103C1","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1378\/chest.11-2888","article-title":"The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe","volume":"142","year":"2012","journal-title":"Chest"},{"key":"key\n\t\t\t\t20180103092541_afx103C2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ijcard.2014.12.063","article-title":"Prevalence of atrial fibrillation and its risk factors in rural China: a cross-sectional study","volume":"182","year":"2015","journal-title":"Int J Cardiol"},{"key":"key\n\t\t\t\t20180103092541_afx103C3","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","year":"1991","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180103092541_afx103C4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","year":"2007","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t20180103092541_afx103C5","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1161\/CIRCULATIONAHA.106.653048","article-title":"Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation","volume":"115","year":"2007","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180103092541_afx103C6","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1345\/aph.1R515","article-title":"National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries","volume":"47","year":"2013","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180103092541_afx103C7","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1161\/01.STR.0000209239.71702.ce","article-title":"Translating the results of randomized trials into clinical practice: the challenge of warfarin candidacy among hospitalized elderly patients with atrial fibrillation","volume":"37","year":"2006","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180103092541_afx103C8","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180103092541_afx103C9","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/S0140-6736(16)31257-0","article-title":"Stroke prevention in atrial fibrillation","volume":"388","year":"2016","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180103092541_afx103C10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1160\/TH16-03-0203","article-title":"Dabigatran in real-world atrial fibrillation. Meta-analysis of observational comparison studies with vitamin K antagonists","volume":"116","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180103092541_afx103C11","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","year":"2010","journal-title":"Int J Surg"},{"key":"key\n\t\t\t\t20180103092541_afx103C12","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group","volume":"283","year":"2000","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20180103092541_afx103C13"},{"key":"key\n\t\t\t\t20180103092541_afx103C14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180103092541_afx103C15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","year":"1994","journal-title":"Biometrics"},{"key":"key\n\t\t\t\t20180103092541_afx103C16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","year":"1997","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180103092541_afx103C17","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1161\/CIRCEP.113.000858","article-title":"Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation","volume":"7","year":"2014","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"key\n\t\t\t\t20180103092541_afx103C18","doi-asserted-by":"crossref","first-page":"454","DOI":"10.5414\/CP201996","article-title":"Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications","volume":"52","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180103092541_afx103C19","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ahj.2012.01.017","article-title":"Safety and effectiveness of antithrombotic strategies in older adult patients with atrial fibrillation and non-ST elevation myocardial infarction","volume":"163","year":"2012","journal-title":"Am Heart J"},{"key":"key\n\t\t\t\t20180103092541_afx103C20","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S0140-6736(07)61233-1","article-title":"Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial","volume":"370","year":"2007","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180103092541_afx103C21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ageing\/afl129","article-title":"A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)","volume":"36","year":"2007","journal-title":"Age Ageing"},{"key":"key\n\t\t\t\t20180103092541_afx103C22","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1161\/01.STR.31.4.822","article-title":"Adverse outcomes and predictors of underuse of antithrombotic therapy in medicare beneficiaries with chronic atrial fibrillation","volume":"31","year":"2000","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180103092541_afx103C23","first-page":"697","article-title":"The safety and adequacy of antithrombotic therapy for atrial fibrillation: a regional cohort study","volume":"56","year":"2006","journal-title":"Br J Gen Pract"},{"key":"key\n\t\t\t\t20180103092541_afx103C24","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1161\/STROKEAHA.114.007199","article-title":"Stroke and major bleeding risk in elderly patients aged \u226575 years with atrial fibrillation: the Loire Valley atrial fibrillation project","volume":"46","year":"2015","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180103092541_afx103C25","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1253\/circj.CJ-15-0621","article-title":"Use of warfarin in elderly patients with non-valvular atrial fibrillation\u2014subanalysis of the J-RHYTHM Registry","volume":"79","year":"2015","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20180103092541_afx103C26","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) study","volume":"58","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180103092541_afx103C27","first-page":"i3189","article-title":"Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study","volume":"353","year":"2016","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180103092541_afx103C28","first-page":"28","article-title":"A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants","volume":"3","year":"2016","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"key\n\t\t\t\t20180103092541_afx103C29","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1161\/CIRCULATIONAHA.115.015710","article-title":"Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study","volume":"132","year":"2015","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180103092541_afx103C30","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","year":"2016","journal-title":"JAMA Intern Med"},{"key":"key\n\t\t\t\t20180103092541_afx103C31","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s40256-016-0189-9","article-title":"Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US Medicare Part D data","volume":"17","year":"2017","journal-title":"Am J Cardiovasc Drugs"},{"key":"key\n\t\t\t\t20180103092541_afx103C32","doi-asserted-by":"crossref","first-page":"pii:e001798","DOI":"10.1161\/JAHA.115.001798","article-title":"Effectiveness and safety of dabigatran and warfarin in real-world US patients with non-valvular atrial fibrillation: a retrospective cohort study","volume":"4","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20180103092541_afx103C33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.hrthm.2015.09.015","article-title":"Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation","volume":"13","year":"2016","journal-title":"Heart Rhythm"},{"key":"key\n\t\t\t\t20180103092541_afx103C34","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1160\/TH15-06-0497","article-title":"Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation","volume":"114","year":"2015","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180103092541_afx103C35","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1160\/TH15-03-0247","article-title":"Dabigatran use in elderly patients with atrial fibrillation","volume":"115","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180103092541_afx103C36","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1161\/CIRCULATIONAHA.110.004747","article-title":"Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial","volume":"123","year":"2011","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180103092541_afx103C37","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.amjcard.2014.06.015","article-title":"Efficacy and cost-effectiveness of dabigatran etexilate versus warfarin in atrial fibrillation in different age subgroups","volume":"114","year":"2014","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180103092541_afx103C38","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","article-title":"Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180103092541_afx103C39","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180103092541_afx103C40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1161\/CIRCULATIONAHA.113.005008","article-title":"Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)","volume":"130","year":"2014","journal-title":"Circulation"},{"key":"key\n\t\t\t\t20180103092541_afx103C41","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1253\/circj.CJ-13-1324","article-title":"Rivaroxaban vs. warfarin in Japanese patients with non-valvular atrial fibrillation in relation to age","volume":"78","year":"2014","journal-title":"Circ J"},{"key":"key\n\t\t\t\t20180103092541_afx103C42","doi-asserted-by":"crossref","first-page":"pii:e003432","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"key\n\t\t\t\t20180103092541_afx103C43","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1160\/TH16-05-0403","article-title":"Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysis","volume":"116","year":"2016","journal-title":"Thromb Haemost"},{"key":"key\n\t\t\t\t20180103092541_afx103C44","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1161\/STROKEAHA.116.016275","article-title":"Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation: systematic review and meta-analysis","volume":"48","year":"2017","journal-title":"Stroke"},{"key":"key\n\t\t\t\t20180103092541_afx103C45","first-page":"e836","article-title":"Efficacy and safety of direct oral anticoagulants compared to warfarin in prevention of thromboembolic events among elderly patients with atrial fibrillation","volume":"8","year":"2016","journal-title":"Cureus"},{"key":"key\n\t\t\t\t20180103092541_afx103C46","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s00228-014-1739-1","article-title":"Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region","volume":"70","year":"2014","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ageing\/article-pdf\/47\/1\/9\/23228160\/afx103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,25]],"date-time":"2019-09-25T19:28:55Z","timestamp":1569439735000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ageing\/article\/47\/1\/9\/4107850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,9,8]]},"published-print":{"date-parts":[[2018,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afx103","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2017,9,8]]}}}